0001567619-20-016413.txt : 20200903 0001567619-20-016413.hdr.sgml : 20200903 20200903160648 ACCESSION NUMBER: 0001567619-20-016413 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200901 FILED AS OF DATE: 20200903 DATE AS OF CHANGE: 20200903 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ALBRECHT DETLEF CENTRAL INDEX KEY: 0001286642 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39041 FILM NUMBER: 201159348 MAIL ADDRESS: STREET 1: SATSUMA PHARMACEUTICALS, INC. STREET 2: 400 OYSTER POINT BOULEVARD, SUITE 221 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Satsuma Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001692830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813039831 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 OYSTER POINT BOULEVARD STREET 2: SUITE 221 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 64080 BUSINESS PHONE: 415-505-0809 MAIL ADDRESS: STREET 1: 400 OYSTER POINT BOULEVARD STREET 2: SUITE 221 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 64080 4 1 doc1.xml FORM 4 X0306 4 2020-09-01 0 0001692830 Satsuma Pharmaceuticals, Inc. STSA 0001286642 ALBRECHT DETLEF C/O SATSUMA PHARMACEUTICALS, INC. 400 OYSTER POINT BOULEVARD, SUITE 221 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Medical Officer Common Stock 2020-09-01 4 M 0 1000 4.56 A 21212 D Common Stock 2020-09-01 4 S 0 1000 22.21 D 20212 D Stock Option (Right to Buy) 4.56 2020-09-01 4 S 0 1000 0 D 2029-05-16 Common Stock 1000 67468 D Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. The transaction was executed in multiple trades in prices ranging from $21.93 to $22.77, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The option vest and become exercisable in successive, equal monthly installments over four years measured from May 15, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. /s/ Thomas P. O'Neil as Attorney in Fact for Detlef Albrecht, M.D. 2020-09-03